Business · 07/12/2020Updated: 10/17/2026 · 1 min read
FDA Awards Priority Review Voucher to Y-mAbs Therapeutics for Rare Pediatric Disease Product DANYELZA
Summary
The FDA has awarded a priority review voucher to Y-mAbs Therapeutics, Inc. for its rare pediatric disease product DANYELZA, following a review of the product's eligibility under the FD&C Act and FDASIA.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →